It is anticipated that the new LCDs will limit reimbursement of CAMPs for diabetic foot ulcers and venous leg ulcers to those with a strong evidence base, and then for up to four applications only, unless a clinical case can be made for longer term use. This will have implications for both patients and health-care providers. This session will outline what it means for you.

Use of more than four applications of CAMPs is only likely to be permitted by the forthcoming the LCDs for diabetic foot ulcers and venous leg ulcers if certain clinical criteria are met. This session will advise on how to justify this using the Kx modifier.

Only access to CAMPs with a robust evidence base will be allowed by the new LCDs. But the evidence base for many CAMPs is highly variable, and is not necessarily an indication of their efficacy and cost-effectiveness. In this session, a panel will debate the minimum evidence requirements for all CAMPs going forward.

There are fears that the pending restrictions to reimbursement will extend to a broader range of indications such as tunnels, post-Mohs and even pressure ulcers, depriving patients of much-needed access. This session will survey the published and experiential evidence on the efficacy of CAMPs on these wound types, and propose how to preserve access to them.

In honour of the late and much-missed Dr Gregory Schultz, this presentation will describe how this Program will support up-and-coming CAMPs providers, to help them reach their full potential and move the discipline forward.

Use of CAMPs on diabetic foot ulcers is well established, with a growing evidence base on its clinical efficacy and cost-effectiveness. This session will outline the latest research findings, which give real insight into accelerated healing rates and cost savings that can be achieved with this technology.

Recent research is making a strong case for the clinical and economic benefits of using CAMPs on venous leg ulcers. This talk will explore the latest evidence for this indication, pointing to the real difference these advanced products can make to patient outcomes.

Industry and healthcare providers are in a symbiotic relationship, with wound-care providers providing feedback and direction for industry, and companies producing the technical innovations that enable physicians to achieve better patient outcomes. In this open-forum debate, representatives from health care and industry will discuss how the two parties can support each other more to mutual advantage.

In this session, a panel of clinical experts will present a selection of case studies on the use of CAMPs on complex wounds. In an open discussion, attendees and presenters will explore options and approaches to the care of each wound.